Eric Van Cutsem Selected Research

thiamine triphosphorate (TTP)

1/2022	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials.
8/2010	Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
11/2006	Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
2/2005	Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
6/2004	XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric Van Cutsem Research Topics

Disease

132	Colorectal Neoplasms (Colorectal Cancer) 04/2024 - 04/2002
129	Neoplasms (Cancer) 05/2024 - 07/2004
49	Adenocarcinoma 05/2024 - 08/2005
47	Disease Progression 12/2023 - 01/2004
39	Stomach Neoplasms (Stomach Cancer) 05/2024 - 01/2002
30	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2007
29	Colonic Neoplasms (Colon Cancer) 11/2022 - 04/2002
22	Pancreatic Neoplasms (Pancreatic Cancer) 11/2023 - 03/2004
21	Neutropenia 01/2023 - 01/2004
20	Fatigue 10/2023 - 02/2011
19	Neuroendocrine Tumors (Neuroendocrine Tumor) 06/2023 - 01/2010
16	Rectal Neoplasms (Rectal Cancer) 09/2022 - 02/2005
14	Hypertension (High Blood Pressure) 01/2023 - 09/2009
13	Microsatellite Instability 01/2024 - 09/2009
12	Diarrhea 01/2023 - 01/2007
9	Nausea 12/2023 - 01/2004
8	Stomatitis 01/2018 - 01/2004
7	Vomiting 01/2023 - 01/2007
7	Exanthema (Rash) 02/2015 - 10/2007
6	Thrombocytopenia (Thrombopenia) 10/2021 - 04/2013
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2019 - 01/2005
5	Abdominal Pain (Pain, Abdominal) 04/2023 - 03/2011
5	Anemia 01/2020 - 02/2011
5	Carcinoma (Carcinomatosis) 10/2018 - 12/2004
5	Febrile Neutropenia 01/2017 - 01/2013
5	Carcinoid Tumor (Carcinoid) 12/2015 - 01/2004
4	Acute Kidney Injury (Acute Renal Failure) 12/2023 - 01/2013
4	Hepatocellular Carcinoma (Hepatoma) 11/2023 - 08/2010
4	Cholangiocarcinoma 09/2023 - 01/2018
4	Hand-Foot Syndrome 01/2023 - 01/2004
4	Inflammation (Inflammations) 01/2022 - 01/2018
3	Pneumonia (Pneumonitis) 12/2023 - 01/2017
3	Esophageal Squamous Cell Carcinoma 10/2023 - 10/2022
3	Asthenia 01/2023 - 02/2011
3	Heart Arrest (Cardiac Arrest) 01/2023 - 01/2019
3	Hemorrhage 01/2023 - 05/2011
3	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 04/2022 - 09/2011

Drug/Important Bio-Agent (IBA)

53	Fluorouracil (Carac)FDA LinkGeneric 01/2023 - 04/2002
36	ErbB Receptors (EGF Receptor)IBA 12/2023 - 07/2004
36	Cetuximab (Erbitux)FDA Link 10/2023 - 07/2004
35	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2023 - 04/2002
34	Leucovorin (Folinic Acid)FDA Link 01/2023 - 04/2002
33	Irinotecan (Camptosar)FDA LinkGeneric 10/2022 - 04/2002
31	Bevacizumab (Avastin)FDA Link 11/2023 - 12/2004
31	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2004
23	Gemcitabine FDA Link 10/2023 - 03/2004
22	Capecitabine (Xeloda)FDA Link 01/2023 - 04/2002
20	Monoclonal AntibodiesIBA 01/2023 - 08/2005
18	Panitumumab (Vectibix)FDA Link 12/2023 - 01/2007
17	Cisplatin (Platino)FDA LinkGeneric 12/2023 - 08/2005
17	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2021 - 01/2007
16	pembrolizumabIBA 12/2023 - 03/2019
13	trifluridine tipiracil drug combinationIBA 02/2024 - 05/2015
10	Trastuzumab (Herceptin)FDA Link 12/2023 - 08/2010
10	regorafenibIBA 01/2023 - 01/2013
10	RamucirumabIBA 10/2021 - 10/2014
10	Everolimus FDA Link 01/2018 - 01/2010
9	Docetaxel (Taxotere)FDA Link 10/2022 - 01/2004
9	afliberceptIBA 01/2020 - 10/2012
8	DNA (Deoxyribonucleic Acid)IBA 06/2023 - 04/2008
8	Paclitaxel (Taxol)FDA LinkGeneric 10/2022 - 10/2014
7	PlatinumIBA 12/2023 - 04/2012
7	130-nm albumin-bound paclitaxelIBA 10/2023 - 10/2013
7	Octreotide (Sandostatin)FDA LinkGeneric 06/2023 - 04/2010
7	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2023 - 12/2017
6	NivolumabIBA 05/2024 - 10/2018
6	binimetinibIBA 04/2024 - 10/2019
6	Peptide Receptors (Peptide Receptor)IBA 01/2022 - 01/2013
6	Radioisotopes (Radionuclides)IBA 01/2022 - 01/2013
6	Angiogenesis InhibitorsIBA 01/2019 - 01/2011
6	XELOXIBA 11/2015 - 06/2004
5	Immune Checkpoint InhibitorsIBA 04/2024 - 08/2021
5	encorafenibIBA 10/2023 - 10/2019
5	Proteins (Proteins, Gene)FDA Link 04/2023 - 08/2010
5	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2023 - 03/2011
5	LigandsIBA 01/2022 - 10/2009
5	thiamine triphosphorate (TTP)IBA 01/2022 - 06/2004
5	Sodium Glutamate (Accent)IBA 11/2021 - 07/2013
5	ParaffinIBA 04/2014 - 04/2007
5	Tyrosine Kinase InhibitorsIBA 10/2012 - 08/2005
4	napabucasinIBA 04/2023 - 04/2019
4	human ERBB2 proteinIBA 01/2023 - 08/2010
4	Epidermal Growth Factor (EGF)IBA 01/2023 - 04/2002
4	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 10/2020 - 01/2015
4	Sorafenib (BAY 43-9006)FDA Link 01/2020 - 02/2013
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2012 - 08/2005
4	AntibodiesIBA 12/2010 - 05/2007
3	IpilimumabIBA 04/2024 - 10/2018
3	Antineoplastic Agents (Antineoplastics)IBA 02/2024 - 02/2017
3	tislelizumabIBA 10/2023 - 10/2022
3	Lipase (Acid Lipase)FDA Link 01/2023 - 06/2015

Therapy/Procedure

112	Therapeutics 12/2023 - 04/2002
96	Drug Therapy (Chemotherapy) 05/2024 - 01/2002
14	Adjuvant Chemotherapy 12/2023 - 08/2004
8	Chemoradiotherapy 09/2022 - 01/2002
8	Radiotherapy 08/2021 - 12/2004
7	Neoadjuvant Therapy 09/2022 - 03/2004
4	Microspheres (Microsphere) 08/2020 - 08/2010
3	Colectomy 04/2022 - 09/2011
3	Cytoreduction Surgical Procedures 01/2022 - 07/2012